Trial
NCT05823480
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Acute Myeloid Leukemia
Intervention
Allogeneic Hematopoietic Stem Cell Transplantation
Why stopped
Withdrawn -ctms
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-09-19